Shield Therapeutics (FRA:1JS) EBIT per Share : €-0.04 (TTM As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics EBIT per Share?

Shield Therapeutics's EBIT per Share for the six months ended in Jun. 2024 was €-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.04.

During the past 3 years, the average EBIT per Share Growth Rate was -23.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was -5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Shield Therapeutics's EBIT per Share or its related term are showing as below:

FRA:1JS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32.9 Med: -14 Max: 53.8
Current: -23.6

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Shield Therapeutics was 53.80% per year. The lowest was -32.90% per year. And the median was -14.00% per year.

FRA:1JS's 3-Year EBIT Growth Rate is ranked worse than
86.12% of 836 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs FRA:1JS: -23.60

Shield Therapeutics's EBIT for the six months ended in Jun. 2024 was €-12.87 Mil.

Shield Therapeutics EBIT per Share Historical Data

The historical data trend for Shield Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics EBIT per Share Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.09

-0.02

-0.12

-0.20

-0.04

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial															-0.06	-0.13	-0.02	-0.03	-0.02

Shield Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Shield Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-28.756	/	722.544
=	-0.04

Shield Therapeutics's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-12.871	/	782.056
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04

Shield Therapeutics (FRA:1JS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Shield Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (FRA:1JS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SHIEF:USA STX:UK

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines

No Headlines